| |
|
|
BROOKLYN PARK, MINN. - Fremont, Calif.-based Protein Design Labs has opened a 210,000-sf commercial-scale biopharmaceutical manufacturing facility in Brooklyn Park , Minn. The facility will produce humanized monoclonal antibodies for the treatment of conditions including cancer and inflammatory diseases.
|
|
 |
Would you like information like this delivered to your email inbox? Subscribe to Tradeline Updates to keep abreast of the latest conference developments, industry news, best practices and more! Sign Up Now!
|
|
Printer Friendly Version
Send to a Friend
